.jpeg)
2026-04-28 04:44:27
This article provides a comprehensive overview of the approved indications, standard dosages for adults and children, administration methods, missed dose and vomiting management principles, as well as dose adjustments for special populations and adverse reaction management of the targeted drug entrectinib.
2026-04-28 04:28:10
This article provides a detailed analysis of the characteristics, mechanisms, high-risk factors, and clinical management points of bleeding risk associated with tepotinib in the treatment of MET-mutated non-small cell lung cancer, helping patients and healthcare professionals scientifically evaluate medication safety.
2026-04-28 04:21:32
This article systematically compares the mechanisms of action, clinical efficacy, side effect profiles, and applicable populations of lomustine and temozolomide, two alkylating antineoplastic agents, providing professional reference for treatment selection in patients with glioma and other tumors.
2026-04-28 03:25:11
This article provides a detailed analysis of the mechanisms of action and clinical therapeutic positioning of tepotinib and osimertinib, exploring the theoretical basis, research progress, and safety considerations of their combination therapy for patients with non-small cell lung cancer.
2026-04-28 03:18:38
This article provides a detailed analysis of the mechanism of action, tumor shrinkage logic, and efficacy evaluation methods of pazopanib, an anti-angiogenic targeted drug, to help patients with renal cell carcinoma and soft tissue sarcoma fully understand its therapeutic value.
2026-04-24 06:39:34
Tabrecta (Capmatinib) is an oral targeted drug designed for advanced non-small cell lung cancer (NSCLC) with METex14 skipping mutations. By inhibiting aberrant MET protein, it offers tumor shrinkage and prolonged response, alongside manageable side effects.
2026-04-23 05:36:07
Study reveals pazopanib’s potential in cutaneous angiosarcoma, offering improved survival and manageable safety despite not meeting PFS endpoint.
2026-04-22 07:26:16
As a bispecific T cell engager, Tarlatamab revolutionizes cancer treatment by activating immune attacks. This guide outlines unique immune-related adverse events (irAEs) and global management strategies.
2026-04-22 07:18:24
As a 3rd-generation EGFR-targeted therapy, Almonertinib offers significant benefits for NSCLC, but safety management—focused on lung toxicity, skin reactions, cardiac risks, and drug interactions—is crucial for long-term use.
2026-04-21 04:14:58
This article specifies home storage requirements for the oral HSP90 inhibitor Pimitespib, covering temperature, humidity and light protection to maintain drug stability and efficacy, supporting long-term medication management.
2026-04-21 02:29:17
Cemiplimab (brand name Libtayo) is a fully human PD-1 immune checkpoint inhibitor developed by Regeneron Pharmaceuticals. Approved by the U.S. FDA in September 2018, it was the first breakthrough therapy for metastatic or locally advanced cutaneous squamous cell carcinoma. By blocking PD-1 ligand binding to activate T-cell anti-tumor activity, it is now approved for the treatment of multiple cancers including cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.
2026-04-20 03:57:16
Mirvetuximab soravtansine (brand name Elahere) is the world's first folate receptor alpha (FRα)-targeted antibody-drug conjugate (ADC) developed by ImmunoGen, USA. It has received full approval from the FDA, EMA, and other global regulatory agencies for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
